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Background: Ras pathway mutation leads to induction and Erk phosphorylation and activation of the Ets1
transcription factor. Ets1 in turn induces cyclin E and cyclin dependent kinase (cdk) 2 to drive cell cycle progression.
Ets1 also induces expression of the epithelial-mesenchymal transition (EMT) transcription factor Zeb1, and thereby
links Ras mutation to EMT, which is thought to drive tumor invasion. Ras pathway mutations are detected by the
Rb1 tumor suppression pathway, and mutation or inactivation of the Rb1 pathway is required for EMT.
Results: We examined linkage between Rb1, Ets1 and Zeb1. We found that an Rb1-E2F complex binds the Ets1
promoter and constitutively limits Ets1 expression. But, Rb1 repression of Zeb1 provides the major impact of Rb1 on
Ets1 expression. We link Rb1 repression of Zeb1 to induction of miR-200 family members, which in turn target Ets1
mRNA. These findings suggest that Ets1 and Zeb1 comprise an amplification loop that is dependent upon miR-200
and regulated by Rb1. Thus, induction of Ets1 when the Rb1 pathway is lost may contribute to deregulated cell
cycle progression through Ets1 induction of cyclin E and cdk2. Consistent with such an amplification loop, we
correlate expression of Ets1 and Zeb1 in mouse and human lung adenocarcinoma. In addition we demonstrate
that Ets1 expression in thymocytes is also dependent upon Zeb1.
Conclusions: Taken together, our results provide evidence of an Rb1-dependent Ets1-Zeb1 amplification loop in
thymocyte differentiation and tumor invasion.
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c-Ets1 was identified as a proto-oncogene based on v-ets
in the genome of the avian leukemia retrovirus E26, and is
the founding member of the Ets family of transcription
factors [1]. Elevated Ets1 expression has been observed in
many invasive and metastatic solid tumors [2] and Over-
expression of Ets1 is sufficient for transformation of
NIH3T3 fibroblasts [3]. In adults, expression of Ets1 be-
comes restricted primarily to lymphoid tissues [4], and
mutation of Ets1 in mice leads to defects in maturation of
lymphocytes [5-7]. Ets1 interacts with Tlx to cause the
critical maturation arrest in T cell acute lymphoblastic* Correspondence: y0liu016@louisville.edu
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unless otherwise stated.leukemia [8]. Induction of Ets1 in solid tumors triggers
neovascularization and the epithelial-mesenchymal transi-
tion (EMT) that drives tumor invasion [9,10]. Ras pathway
signaling is critical for normal development, and constitu-
tively activating Ras mutations in tumors short-circuit the
pathway leading to growth factor-independent cell prolif-
eration, neovascularization and EMT [11,12]. Ets1 is phos-
phorylated and activated by Erk phosphorylation when the
Ras pathway is engaged [13-15], and this induction of Ets1
is a mediator of Ras-initiated EMT. Accordingly, a down-
stream target of Ets1 is the EMT transcription factor Zeb1
[16], which is required for maintaining epithelial vs. mes-
enchymal balance in vivo [9]. When induced in response
to Ras mutation, Zeb1 causes transition to an invasive
mesenchymal phenotype [17]. A key sensor of mutant Ras
is the Rb1 family of cell cycle regulators, whose activation
in response to Ras mutation represses Zeb1 and blocks
EMT [18].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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miR-200 family members [19]. miR-200 also represses
Zeb1, but in a double negative loop Zeb1 binds the pro-
moters of miR-200 family members and represses their
expression [20,21]. Such findings raised the possibility
that Zeb1 might feedback to induce Ets1 via its repres-
sion of miR-200, and that Rb1 might also influence Ets1
expression via its regulation of Zeb1. Here, we examined
potential linkage between Rb1, Ets1, and Zeb1. Although
Rb1 can interact with genes in a cell cycle-dependent
fashion to regulate proliferation, it is also found consti-
tutively at other genes including pro-apoptotic factors
and mutation or inactivate of Rb1 is required for induc-
tion of such genes [22]. We found here that Rb1 is
present constitutively at the Ets1 promoter and removal
of an Rb1-E2F complex using a dominant negative-E2F
led to induction of Ets1. Thus, Rb1 directly diminishes
the level of Ets1 expression. We also provide evidence
that Zeb1 induces Ets1, and we show that an additional
and major effect of Rb1 on Ets1 expression is mediated
through Rb repression of Zeb1. We link the effect of Zeb1
to its regulation of miR-200, which in turn target Ets1.
Taken together, our results provide evidence of an
amplification loop consisting of Ets1 and Zeb1, which is
mediated by miR-200 and regulated by Rb1. We also
show that Zeb1 and Ets1 are expressed together at the
invasive edge of K-Ras-initiated mouse lung adenocar-
cinomas, and there is a significant correlation between
expression of Ets1 and Zeb1 in human lung adenocar-
cinoma. Like Ets1, Zeb1 is important for thymocyte dif-
ferentiation, and Zeb1(−/−) mice show a reduction in
thymocytes [5,23-27]. Importantly, we demonstrate that
mutation of Zeb1 eliminates Ets1 expression in thymo-
cytes, demonstrating dependence of Ets1 expression on
Zeb1 in thymocytes, and thus potentially linking the
Zeb1 phenotype in T cell differentiation to a lack of Ets1
expression.
Methods
Cells and cell culture
Rb family triple knockout (TKO) mouse embryo fibro-
blasts and control wild-type fibroblasts have been de-
scribed and were a kind gift from T. Jacks and J. Sage [28].
Three independent TKO and wild-type isolates were used
with similar results. Mouse Zeb1 wild type and mutant fi-
broblasts were isolated from crosses of mice heterozygous
for Zeb1 and genotyped as described [23]. The human
osteosarcoma U2OS cells expressing IPTG-inducible
p16INK4a were described previously [29], as were the
U2OS cells expressing both IPTG-inducible p16INK4a and
DN-E2F-mER [30]. U2OS cells were cultured with 1 mM
IPTG in the medium for either one or three days to in-
duce p16INK4a, or with 100 nM Tamoxifen (OHT) for one
day to induce mER-DB-E2F expression. For combinedtreatments, cells were treated with IPTG for one day, and
then OHT was added along with the IPTG for an add-
itional day. All the above fibroblast cells were cultured in
DMEM medium with 10% fetal bovine serum (FBS) and
antibiotics at 10% CO2 and 37°C.
Zeb1 shRNA construct and lentivirus preparation
We have described the lentiviral shRNA knockdown of
Zeb1 protein and mRNA in detail previously
[17,18,31,32,33].
Immunohistochemistry
Mouse embryos and adult lung tumor tissues were fixed
with 10% formalin, paraffin-embedded, and sectioned at
5 μm. Primary antibodies for Zeb1 (kind gift from Dr.
Douglas Darling), CD3 (kind gift from Dr. Qingxian Lu),
E-cadherin (Santa Cruz Technology), Ets1 (Santa Cruz
Biotechnology) and the secondary antibodies are detailed
in Additional file 1: Table S1. The slides were mounted
with coverslips using anti-fade medium Permount with
DAPI (Fisher) and viewed under a Zeiss fluorescent
microscope.
K-RasLA1 mice
Housing and handling of all mice was in accordance with
procedures approved by the University of Louisville Institu-
tional Animal Care and Use Committee (IACUC). K-RasLA1
mice [34] in a C57BL6 background were obtained from
Jackson Laboratory. PCR genotyping was as described
previously [34].
Human lung adenocarcinoma microarray analysis
No human tissue was utilized in this study. The proc-
essed microarray data were used from previously pub-
lished work (the NCBI database GSE_1969163) that
contains 59 samples of human lung adenocarcinomas se-
quenced for mutations in K-RAS and EGFR and patient
matched control lung tissue [35]. The expression levels
of Zeb1 and Est1 mRNAs were selected for calculating
Pearson correlation score.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were based on the UpState protocol (http://
www.tc.umn.edu/~muell002/Laboratory/protocols/X-ChIP.
htm) using formaldehyde to crosslink genomic DNA of
wild-type MEF cells. The chromatin was sheared to an
average length of 300–500 bp. Monoclonal antibodies for
Rb (Santa Cruz sc-50), E2F1 (Santa Cruz sc-193), E2F4
(Santa Cruz sc-866), and polyclonal antiserum for Zeb1 (a
kind gift from Dr. Douglas Darling) were used for immuno-
precipitation. Equal amounts of anti-IgG or pre-immune
serum were used as controls. The sequence of primers for
Ets1 promoter and the expected size of the PCR products
are show in Additional file 2: Table S2. ChIP PCR reactions
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but with additional 1% BSA and 1% DMSO, and the PCR
programs usually had a higher annealing temperature (e.g.
60 – 68°C) and longer extension time (e.g. 1 minute).
Protein extraction and electrophoretic mobility shift assay
(EMSA)
The cultured adherent wild-type MEF cells were scraped
off and lysed in the lysis buffer (50 mM Tris/HCl, pH7.4,
100 mM NaCl, 0.5% Triton X-100, 0.5% NP-40) on ice for
20 minutes, followed by 10-minute centrifuge at 13,000 g,
the supernatant was thereafter collected as non-denatured
protein extract immediately for the gel shift assay. Based on
the sequence alignment of both human and mouse Ets1
promoters, an aligned 24-bp short sequence (5′-TCCA-
TAATTTGCCACTGATAGAT-3′) with a putative E2F site
(TTTGCCAC) is selected for synthesis of the double-
strand oligos with and without artificial mutation of the
E2F site (the mutant oligo sequence: 5′-TCCATAACC-
TAGCTAGATAGAT-3′). Twenty μg of the above crude
protein lysate was mixed with 10 pmol of each of the
double-strand oligos in a 10-μl protein-DNA binding buffer
(5 mM Tris/HCl pH7.4, 100 mM KCl, 100 μM dithiothrrei-
tol, 100 μM EDTA), and incubated at RT for 40 minutes.
The binding reactions without protein lysate or oligos were
served as background controls. All the binding reaction
samples were separated on a 6% native polyacrylamide gel
in 0.5× TBE buffer at constant 200 V and RT for 20 minutes.
The finished gel was stained with 10,000× diluted SYBR
green (Molecular Probe) in 0.5× TBE buffer at RT for 20 mi-
nutes, and then visualized under UV light.
RNA extraction and real-time PCR
Total cellular RNA was extracted using TRIzol solution
(Invitrogen, Carlsbad, California). Using Primer3 (http://
bioinfo.ut.ee/primer3-0.4.0/), primer sets were designed to
generate 150–250 base pair PCR products that bridge two
separate exons. Primer sequence, melting temperature
(Tm), and PCR product sizes are listed in Additional file 2:
Table S2. First-strand complementary DNA (cDNA) syn-
thesis was carried out in 20-μl reactions containing 1-2 μg
of total RNA, 500 ng random hexamers, 10 mM dithiothre-
itol, 500 μM dNTP mix, 40 U RNaseOUT™ ribonuclease
inhibitor, and 200 U M-MLV reverse transcriptase, at 37°C
for 1 h according to the manufacturer’s protocol (Invitro-
gen, Carlsbad, California). Real-time quantitative PCR was
performed in 25-μl reaction volumes containing 0.25-μl ali-
quots of cDNA, gene-specific primer pairs, and SYBR
Green I fluorescent dye (Molecular Probes, Eugene, Ore-
gon), in an Mx3000P Real-Time PCR System (Stratagene,
Cedar Creek, Texas), according to the manufacturer’s in-
structions. The PCR cycle parameters were set at 95°C for
20 sec, 60°C for 30 sec, and 72°C for 30 sec, for a total of
not more than 45 cycles. The fluorescent intensity of SYBRgreen was monitored at the end of each extension step;
relative amounts of the target cDNA was estimated by the
threshold cycle (Ct) number, and normalized to two in-
ternal control genes, β-actin (ACTB) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Three independent
samples were analyzed for each condition and/or cell type,
and each sample was compared in at least 3 independent
RT-PCR amplifications.
MicroRNA detection
The quantitative RT-PCR to detect miRNAs is as described
[36]. Briefly, polyadenylation of at least 5 μg of the total
RNA was completed by poly(A) polymerase kit (PAP,
Ambion) in a 20 μl of reaction volume according to manu-
facturer’s instruction. The polyadenylated RNA was there-
after directly utilized for cDNA preparation using a reverse
transcription kit (M-MLV reverse transcriptase, Invitrogen)
and an adaptor primer (5′-GCGAGCACAGAATTAA-
TACGACTCACTATAGG(T) 12VN*-3′) in a 40 μl of reac-
tion volume. Real-time quantitative PCR was performed
using a universal primer (5′-GCGAGCACAGAATTAA-
TACGAC-3′) and a miRNA-specific primer (Additional file
2: Table S2) as described above.
Results
The Rb1 family represses Ets1 expression
Mutations in Ras trigger activation of Rb1 and tumor
suppressing oncogene-induced senescence [17,37]. Thus,
mutation or inactivation of the Rb1 pathway, which is a
hallmark of cancers, is critical for Ras-initiated tumor
formation. Ets1 is phosphorylated and activated by Erk
in response to Ras signaling [13], and in turn Ets1 in-
duces cyclin E and cdk2 to drive cell cycle progression
[38]. Therefore, we wondered if Rb1 might repress Ets1.
Indeed, mutation of Rb1 in primary cultures of mouse em-
bryo fibroblasts (MEFs) led to induction of Ets1, and Ets1
was further induced when all three closely related Rb1 fam-
ily members (Rb1, Rbl1 and Rbl2) were mutated to gener-
ate triple knockout (TKO) MEFs (Figure 1). These results
suggest that Ets1 is under repression by the Rb1 family.
E2F1-Rb1 binds the Ets1 promoter and constitutively
repressed the gene
We used chromatin immunoprecipitation (ChIP) assay
and electrophoretic mobility shift assay (EMSA) to deter-
mine whether Rb1 is bound to the Ets1 promoter and
whether removal of its putative binding site of E2F family,
the Rb1 DNA binding partner, diminishes the binding.
Rb1 does not bind directly to DNA, but it can be tethered
to promoters through interaction with the E2F family of
transcription factors [39]. Some E2Fs (e.g. E2F1) contain a
transactivation domain, while other E2Fs lack a transacti-
vation domain (e.g., E2F4). Binding to Rb1 blocks the
transactivation domain of E2Fs, but Rb1 also interacts
Figure 1 Ets1 is under repression by the Rb1 family. Mutation of
Rb1 in primary cultures of mouse embryo fibroblasts (MEFs) led to
significant (p< 0.05) induction of Ets1 mRNA, and Ets1 mRNA was further
very significantly (p< 0.01) induced when all three closely related Rb1
family members (Rb1, Rbl1 and Rbl2) were mutated to generate triple
knockout (TKO) MEFs. Real time PCR results normalized to actin mRNA
are shown.
Figure 2 An Rb1-E2F1 complex binds the Ets1 promoter and constitu
Ets1 promoter sequences showing two regions of higher similarity that conta
mouse Ets1 promoter with two putative E2F sites. SST: start site of transcriptio
of Rb1 and E2F1 to the Ets1 promoter together with the positive control histo
control serum and mock indicates no added DNA. (D) Electrophoretic mobilit
crude protein lysate to the target DNA oligo upon mutation of its putative E2
indicates a mutant oligo with a mutated E2F site.
Dean et al. BMC Molecular Biology  (2015) 16:8 Page 4 of 10with epigenetic modifiers to form an active repressor [29].
Both human and mouse Ets1 promoters have two major
similar regions that each contains a perfectly aligned con-
sensus E2F binding site (Figure 2A and B). ChIP assays
showed that Rb1 and E2F1, but not E2F4, were bound to
the Ets1 promoter in vivo (Figure 2C), while EMSA dem-
onstrated that mutation of the putative E2F site reduced
the specific binding of the crude protein lysate to the tar-
get DNA oligo in vitro (Figure 2D), suggesting that Rb1-
E2F1 complex specifically binds to the putative E2F site of
the Ets1 promoter. Next, we wondered if Rb1 was acting
at the Ets1 promoter to block transactivation by E2F, or if
Rb1 was serving as an active repressor. Previously we de-
scribed a dominant negative (DN) form of E2F consisting
of the DNA binding domain fused to a mutant estrogen
receptor (DN-E2F-mER). Following hydroxyl-tamoxifen
(OHT) treatment, DN-E2F-mER is translocated to the nu-
cleus where it displaces E2F and E2F-Rb1 complexes from
promoters. In the same cell, an IPTG-inducible p16 gene
is also included to assemble E2F-Rb complexes at target
genes following IPTG treatment [40] (Figure 2A). If E2F
were serving a transactivation function at the Ets1 pro-
moter, then DN-E2F-mER would cause repression, but if
an E2F-Rb1 complex were serving as a constitutive repres-
sor, DN-E2F-mER would cause induction. We found thattively represses the gene. (A) Alignment of both human and mouse
ins consensus E2F binding sites (boxed). (B) A schematic diagram of
n. (C) Chromatin immunoprecipitation (ChIP) assay demonstrates binding
ne H3. Input indicates the DNA used for immunoprecipitation, IgG is
y shift assay (EMSA) demonstrates reduction of the specific binding of the
F site. ‘wt’ denotes a wild-type oligo with a putative E2F site while ‘mt’
Figure 3 Regulation of Ets1, Rrm2 and Ntf3 expression by Rb-E2F complex. (A) Diagram showing a dominant negative (DN) form of
E2F where the E2F DNA binding domain is fused to the mutant hydroxyl-tamoxifen (OHT)-dependent estrogen receptor (m-ER) displacing E2F
and Rb-E2F from a promoter following OHT treatment. IPTG-inducible p16 expression is shown leading to assembly of E2F-Rb complexes at target
genes [40]. (B) Human U2OS cells were treated with IPTG, OHT or IPTG + OHT as described in Material and Methods. Real time PCR was used to
measure mRNA levels of Ets1 (C), Rrm2 (D) and Ntf3 (E). “Ctrl” indicates untreated control cells. Results were normalized to β-actin mRNA. Rrm2,
ribonucleotide reductase, Ntf3, neurotrophin 3.
Figure 4 Zeb1 induces Ets1 expression, and it mediates much of the effect of Rb1 on Ets1 expression. (A) Zeb1 mutation leads to a gene
dosage-dependent downregulation of Ets1 expression. Real time PCR is shown and results are normalizaed to β-actin mRNA when the Western
blots show similar result accordingly. (B) Zeb1 mutation leads to a gene dosage-dependent induction of miR-200 family members. Real time PCR
is shown. (C) Rb1 family mutation leads to induction of miR-200 family members, and this induction is reversed by lentiviral knockdown of Zeb1
(Zeb1 sh). (D) Zeb1 is induced along with Ets1 as Rb1 family members are mutated. And, knockdown of Zeb1 reverses most of the induction of
Ets1. Real time PCR is shown.
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Figure 5 Ets1 and Zeb1 are expressed at the invasive front of K-Ras initiated mouse lung adenocarcinoma. (A and B) H&E staining
showing the invasive front of an adenocarcinoma (AC) from a K-RasLA1 mouse lung. (C-E) Note immunostaining for E-cadherin (E-cad.) in normal
lung and expression of Zeb1 and Est1 in carcinoma invading into normal lung. Arrows indicate invasive carcinoma.
Figure 6 Correlation between Ets1 and Zeb1 mRNA expression
in human lung adenocarcinomas. A Pearson plot is shown. See
Methods for description of the microarray data base analysis.
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duction of Ets1, demonstrating that E2F1-Rb1 at the pro-
moter is constitutively repressing Ets1 (Figure 3C). Rb1
activity is regulated in a cell cycle dependent fashion by
cyclin dependent kinases (cdks) that hyperphosphorylate
the protein blocking its interaction with E2F [22]. Cdk in-
hibitors such as p16 block the activity of these cdks and
cause accumulation of constitutively active Rb1 which as-
sociates with E2F at the promoter of target genes [41].
Many genes such as Rrm2 are dependent upon phosphor-
ylation/dephosphorylation of Rb1 during the cell cycle and
these genes are further repressed when Rb1 is activated by
expression of p16 (Figure 3D), but other genes such as
Ntf3 that are constitutively repressed by Rb1-E2F are not
further repressed by activation of Rb1 through expression
of p16 (Figure 3E). We previously described expression
of p16 driven by an IPTG-inducible promoter [32]
(Figure 3B). As with Ntf3, we found that induction of p16
had no effect on repression of Ets1 (Figure 3C). Taken to-
gether, these results suggest that E2F-Rb1 is present con-
stitutively at the Ets1 promoter, where it reduces the level
of Ets1 expression in a cell cycle-independent fashion.
Zeb1 repression of the miR-200 family is linked to
induction of Ets1
Zeb1 is a target of the miR-200 family, but in a negative
loop Zeb1 feeds back to repress transcription of miR-200
family members [20,21]. Because miR-200 has been shown
to target Ets1 [19], we wondered if Zeb1 might also affect
expression of Ets1. Indeed, we found that mutation of
Zeb1 in MEFs led to a gene dosage-dependent increase in
expression of Ets1 (Figure 4A). We did not detect Zeb1 at
the Ets1 promoter in ChIP assays (Figure 2C) and induc-
tion of Ets1 coincided with induction of miR-200 as Zeb1alleles were mutated (Figure 4B), suggesting that it is in-
duction of miR-200 when Zeb1 is mutated that is causing
induction of Ets1. It is of note that further down-
regulation of Zeb1 in Zeb1 null MEF cells had little effects
on miR-200 expression (Figure 4B), possibly due to [1] the
level of Zeb1 protein in het MEF cells is low enough to re-
lieve the repression on miR-200 family, further decrease in
Zeb1 expression in null cells will not increase in miR-200
expression accordingly or/and [2] it is also possible that
Zeb1 might down-regulate other unknown factor(s) that
positively regulates expression of miR-200 family at the
same time and thereby makes the regulation network
more complex. Taken together, these results suggest an
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creases transcription of Zeb1, and Zeb1 in turn represses
miR-200 to further elevate Ets1.
Rb1 family repression of Zeb1 is a major component of
inhibition of Ets1 by Rb1
Even though an Rb1-E2F complex binds to the Ets1 pro-
moter to reduce its expression, it is of note that Rb1 also
represses Zeb1 [40], leading us to ask whether Rb1 re-
pression of Zeb1 was also contributing to the Rb1-
dependent downregulation of Ets1. As we demonstrated
previously [16], mutation of Rb1 family members led to
induction of Zeb1 and this induction of Zeb1 was ac-
companied by repression of miR-200 (Figure 4C) and, as
shown above, Ets1 (Figure 1). Knockdown of Zeb1 in the
TKO MEFs using shRNA lenvirirus, as described previ-
ously [17], eliminated much of the induction of Ets1
(Figure 4D), suggesting that induction of Zeb1 and re-
pression of miR-200 as Rb1 family members are mutated
is contributing significantly to the upregulation of Ets1.
These results suggest that Rb1-E2F binds the Ets1 pro-
moter to limit its level of expression, but it is induction
of Zeb1 and in turn repression of miR-200 when the
Rb1 family activity is lost that is responsible for most of
the induction of Ets1.
Ets1 and Zeb1 are expressed at the invasive front
of K-Ras initiated mouse lung adenocarcinoma
Ras pathway signaling causes Erk-dependent activating
phosphorylation of Ets1 [13] and the resulting induction
of Zeb1 is thought to be an important factor in Ras-
initiated EMT (which is opposed by Rb1) [9]. Induction
of Zeb1 leads to transition to a migratory mesenchymal
phenotype and can been seen at the invading front of tu-
mors [17]. We examine expression of Ets1 and Zeb1 in
K-Ras initiated mouse lung adenocarcinomas (Figure 5A
and B). Activation of an oncogenic K-Ras allele by re-
combination in somatic cells is sufficient for spontan-
eous lung cancer in K-RasLA1 mice [34]. In this mouse
model regions of atypical adenomatous hyperplasia
(AAH) becomes evident in bronchial airways, and this
hyperplasia expands to initiate formation of subpleural
precancerous adenomas. Foci of adenocarcinoma in
situ begin to appear within these precancerous lesions
as the first evidence of transition to malignancy, and
these adenocarcinomas subsequently expand and in-
vade into surrounding lung tissue where E-cadherin is
expressed (Figure 5C). In this model, Rb1 is a major
barrier to tumor initiation, and it is inactivated by cdk
hyperphosphorylation in these tumors [28]. Neither
Ets1 nor Zeb1 were expressed in precancerous AAH or
adenomas, but both were expressed at the invasive
edge of adenocarcinomas (results not shown; Figure 5D
and E).Correlation between Ets1 and Zeb1 in human lung
adenocarcinomas
To check if Ets1 also follows Zeb1 expression in human
lung adenocarcinomas, we examined microarrays of 59
human lung adenocarcinomas [35] and compared ex-
pression of Ets1 and Zeb1 mRNAs. We found a signifi-
cant correlation between expression of Ets1 and Zeb1
mRNA in these tumors (Figure 6). Taken together, these
data with mouse and human lung adenocarcinomas are
consistent with the amplification loop we described
above for Ets1 and Zeb1.
Mutation of Zeb1 eliminates Ets1 expression in
differentiating thymocytes
Although the correlation between Ets1 and Zeb1 in lung
adenocarcinoma seen above is consistent with an amplifica-
tion loop between Ets1 and Zeb1, these results are also con-
sistent simply with the previously documented induction of
Zeb1 by Ets1 [9]. Therefore, we next asked whether Ets1
expression is dependent upon Zeb1. Mutation of Zeb1 and
Ets1 both lead to defects in thymocyte differentiation
[23-27]. Zeb1(−/−) mice show a decrease in the number of
thymocytes (Figure 7A, B, C, F, G and H), and we found
that this Zeb1 mutation eliminated Ets1 expression in the
thymocytes (Figure 7D, E, I and J). These results demon-
strate that Ets1 expression in thymocytes is dependent
upon Zeb1, and further confirm the linkage between the
two transcription factors in the defects leading to thymo-
cyte differentiation.
Discussion
Mutation in the Ras pathway leading to growth factor inde-
pendent signaling is frequent in tumors [11,12]. One conse-
quence of Ras mutation is EMT, and this appears to be
mediated at least in part by Erk phosphorylation and activa-
tion of Ets1 and in turn Ets1 induction of the EMT tran-
scription factor Zeb1 [13]. The Ras pathway is under
surveillance by the Rb1 tumor suppressor family, and muta-
tion or inactivation of the Rb1 family is a hallmark of can-
cer required for progression of tumors with a Ras pathway
mutation [22]. One consequence of Rb1 activation in re-
sponse to Ras mutation is to suppress EMT. Our results
suggest that E2F-Rb1 binds constitutively to the Ets1 pro-
moter and limits the level of expression, but a second major
impact of Rb1 on Ets1 expression is mediated through Rb1
repression of Zeb1 [40] and in turn induction of miR-200,
which targets Ets1. We propose that Ets1 and Zeb1 form
an amplification loop that is dependent upon Zeb1 repres-
sion of miR-200 and regulated by the Rb1 family (Figure 8).
We present evidence correlating expression of Ets1 and
Zeb1 in invasive lung adenocarcinoma, suggesting that this
amplification loop is evident in invasive lung cancer. Im-
portantly, we demonstrate that Zeb1 is required for Ets1
expression in differentiating thymocytes providing evidence
Figure 7 Zeb1 mutation eliminates Ets1 expression in differentiating embryonic thymocytes. A-G H&E sections of embryonic day 15.5
wild-type and Zeb1(−/−) embryos showing the thymus (T). Note the decrease in thymocyte number with Zeb1 mutation. (C-J) Immunostaining
showing loss of expression of Ets1 with Zeb1 mutation in differentiating thymocytes. CD3 is a T-cell marker.
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mus. Beyond regulating expression of Zeb1 and EMT, Ets1
also induces expression of cyclin E and cdk2 to drive cell
cycle progression [38]. Rb1 pathway mutation or inactiva-
tion is closely linked to unrestricted cell proliferation [22],
and our results suggest that one component of this unre-
stricted cell cycle progression might be upregulation of
Zeb1 and in turn Ets1 when the Rb1 pathway is lost. Inter-
estingly, two separate transcriptional functions have been
ascribed to Zeb1. Zeb1 binds to DNA through a series of
zinc finger domains, and a C-terminal domain binds to the
co-repressor CtBP to repress transcription [42]. The
N-terminal domain of Zeb1 binds Smads and the transcrip-
tional co-activator p300, and Zeb1 acts as a scaffold for as-
sembly of an active smad-p300 complex at promoters of
TGF and BMP-responsive genes [43]. Two differentFigure 8 Model depicting an Ets1-Zeb1 amplification loop that
is dependent upon miR-200 and regulated by Rb1. See text
for discussion.mutations of Zeb1 have been examined—a gene knockout
and a mutation that deletes the N-terminal smad-p300
binding domain [23,30]. Knockout of Zeb1 leads to lethality
at the end of gestation, with cleft palate, skeletal defects,
disrupted epithelial vs. mesenchymal balance and dimin-
ished thymocyte differentiation [23]. Interestingly, deletion
of the N- terminal domain of Zeb1 eliminates cleft palate
and other skeletal defects, but the thymocyte differentiation
defect persists [30]. These results imply that CtBP-
dependent transcription repression of miR-200 family
members by Zeb1 is important for regulation of Ets1 and
for thymocyte differentiation.
Conclusions
Our results provide evidence of an Rb1-dependent
Ets1-Zeb1 amplification loop that is important in both
cancer and in normal development of the thymus.
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